These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Optimal use of blood and innovative approaches to stem cells, regenerative medicine and donor recruitment. Colligan D; McGowan N; Seghatchian J Transfus Apher Sci; 2014 Apr; 50(2):303-6. PubMed ID: 24642068 [TBL] [Abstract][Full Text] [Related]
3. Scotblood 2007: Tackling local and global issues in transfusion medicine - donor recruitment, effective use of blood, stem cell plasticity, and vCJD. Bessos H; Fraser R; Seghatchian J Transfus Apher Sci; 2008 Feb; 38(1):77-83. PubMed ID: 18282808 [TBL] [Abstract][Full Text] [Related]
4. Scotblood 2010: key presentations of the past, present, and future of transfusion medicine to mark Scottish national blood transfusion service (SNBTS) anniversaries. Bessos H; Fraser R; Seghatchian J Transfus Apher Sci; 2011 Oct; 45(2):213-21. PubMed ID: 21840760 [TBL] [Abstract][Full Text] [Related]
5. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Hewitt PE; Llewelyn CA; Mackenzie J; Will RG Vox Sang; 2006 Oct; 91(3):221-30. PubMed ID: 16958834 [TBL] [Abstract][Full Text] [Related]
6. Scotblood 2008 celebrates 60th anniversary of the NHS through past, present, and future of transfusion medicine, encompassing Hepatitis C Scottish Odyssey, nursing, translational medicine and trauma. Bessos H; Fraser R; Seghatchian J Transfus Apher Sci; 2008 Dec; 39(3):261-8. PubMed ID: 18929514 [TBL] [Abstract][Full Text] [Related]
7. The impact of variant CJD on transfusion practices in the UK. Boulton F Transfus Apher Sci; 2003 Apr; 28(2):107-16. PubMed ID: 12679113 [TBL] [Abstract][Full Text] [Related]
8. Update on the provisional estimation of developing iatrogenic variant Creutzfeldt-Jakob disease from human islet cell transplantation procedures. Tyshenko MG; Bertram L; Li L; ElSaadany S; Samis J; Krewski D; Cashman NR Transplantation; 2014 Jun; 97(12):e73-5. PubMed ID: 24933255 [No Abstract] [Full Text] [Related]
9. Potential role of mesenchymal stromal cells in pancreatic islet transplantation. Hematti P; Kim J; Stein AP; Kaufman D Transplant Rev (Orlando); 2013 Jan; 27(1):21-9. PubMed ID: 23290684 [TBL] [Abstract][Full Text] [Related]
10. vCJD and blood transfusion in the United Kingdom. Hewitt P Transfus Clin Biol; 2006 Nov; 13(5):312-6. PubMed ID: 17188541 [TBL] [Abstract][Full Text] [Related]
11. Methods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: where to set the standard? Sutton JM; Dickinson J; Walker JT; Raven ND Clin Infect Dis; 2006 Sep; 43(6):757-64. PubMed ID: 16912952 [TBL] [Abstract][Full Text] [Related]
13. Insights into the management of emerging infections: regulating variant Creutzfeldt-Jakob disease transfusion risk in the UK and the US. Ponte ML PLoS Med; 2006 Oct; 3(10):e342. PubMed ID: 17076547 [TBL] [Abstract][Full Text] [Related]
14. [Transfusion risk analysis with regard to vCJD in France]. Martin M; Legras JF; Pouchol E; Trouvin JH Transfus Clin Biol; 2006 Nov; 13(5):298-303. PubMed ID: 17188540 [TBL] [Abstract][Full Text] [Related]
15. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion. Wkly Epidemiol Rec; 2000 Nov; 75(47):377-9. PubMed ID: 11144617 [No Abstract] [Full Text] [Related]
16. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause? Chohan G; Llewelyn C; Mackenzie J; Cousens S; Kennedy A; Will R; Hewitt P Transfusion; 2010 May; 50(5):1003-6. PubMed ID: 20230536 [TBL] [Abstract][Full Text] [Related]